ScienceDex / Researcher record
Serena Patricia Koenig
- Brigham and Women's Hospital · Internal Medicine (investigator's affiliation)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
- Program Leader
- R01 Holder
- Early Career
NIH Funding · FY2026
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $1,143,959 | 1 | #12,866 |
| 2025 | $1,170,950 | 3 | #14,010 |
| 2026 | $1,895,930 | 4 | #11,016 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20241 record
- FY20253 records
- FY2026 · selected4 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 7947542Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2026 award categories
- Internal Medicine
FY2026 award records by amount
NIH award records listing Serena Patricia Koenig as a PI. Multi-PI records show the full award amount for context.
- 1R01AI203549-01R01Co-investigatorLANCET-HBV: Hepatitis B Infection in the Era of Long-Acting ARTUniversity of California, Los Angeles · Internal Medicine (NIH department code)$673.2Kaward amount
- 4U01AI170426-05U01Contact PIPRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisBrigham and Women's Hospital · Internal Medicine (investigator's affiliation)$526.3Kaward amount
- 3U01AI170426-05S2U01Contact PIPRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisBrigham and Women's Hospital · Internal Medicine (investigator's affiliation)$365.4Kaward amount
- 3U01AI170426-05S1U01Contact PIPRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisBrigham and Women's Hospital · Internal Medicine (investigator's affiliation)$331Kaward amount
Award organizations
Organizations that administered FY2026 awards listing Serena Patricia Koenig as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardBrigham and Women's Hospital
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Multi-Institutional ResearchAwards at 2 institutions
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Serena Patricia Koenig.